← All Cns Pharmaceuticals, INC filings

Cns Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CNSP
Cns Pharmaceuticals, INC
10-K/A: CNS Pharmaceuticals Files 10-K/A for Governance Updates
CNS Pharmaceuticals, Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding directors, executive compensation, and corporate governance.
NASDAQ
CNSP
Cns Pharmaceuticals, INC
10-K/A: CNS Pharmaceuticals Files Amendment to 10-K to Include Omitted Part III Information
CNS Pharmaceuticals files an amendment to its 2024 annual report on Form 10-K to include information required by Items 10 through 14 of Part III, which were initially omitted.
NASDAQ
CNSP
Cns Pharmaceuticals, INC
10-K: CNS Pharmaceuticals Reports 2024 Results, Focuses on TPI 287 Development After Berubicin Trial Outcome
CNS Pharmaceuticals' 10-K filing reveals a year of strategic shifts, focusing on TPI 287 development and analyzing the path forward after topline data from the Berubicin trial did not meet its primary endpoint.
NASDAQ
CNSP
Cns Pharmaceuticals, INC
10-K: CNS Pharmaceuticals Reports 2023 Financial Results and Provides Business Update
CNS Pharmaceuticals' 2023 annual report details ongoing clinical trials for Berubicin, financial losses, and the need for substantial future funding.